Lifeway Foods Sets A Sales Record, But Q3 EPS Falls 91.3% As Gross Margin Shrinks To 18% And The 2027 Recovery Becomes The Whole Story

Lifeway Foods (NASDAQ: LWAY) delivered the kind of quarter where the top line and the bottom line tell opposite stories. Net sales reached a record $67.8 million, up 18.6% year over year and the company's 28th straight quarter of growth. Earnings collapsed to $0.02 per share, a 91.3% year-over-year decline, from $0.23 a year ago, and net income fell to $0.3 million from $3.5 million. No consensus estimate or Earnings Whisper was available, so the quarter has to be judged on its trajectory rather than on a beat or miss. That trajectory is the central tension. Demand for kefir is outrunning Lifeway's ability to produce it, while the cost of producing it has overwhelmed the economics of each sale.

The quality problem is concentrated in gross margin. Gross margin fell to 18.0% from 28.7% a year earlier. Management attributed the drop to milk, resin-based packaging, ingredients and freight. The sequential slide is more telling: 27.8% in Q4 2025, 27.5% in Q1, 19.5% in Q2 and 18.0% in Q3. Gross profit dollars fell to $12.2 million from $16.4 million, even on $10.7 million more revenue. SG&A leverage improved to 16.2% of sales from 19.6%. That improvement came from general and administrative expense dropping to $4.5 million from $6.2 million, while selling expense actually rose 27%. Below the operating line, interest expense jumped to $340,000 from $21,000, and a $505,000 tax provision on $765,000 of pre-tax income consumed most of what was left.

The balance sheet has also changed character. Lifeway entered 2026 with no debt. It now carries $12.0 million on its line of credit and a $12.0 million note payable. Nine-month capital spending of $22.8 million, tied largely to the Waukesha scale-up, far exceeded operating cash flow of $4.9 million, which itself was less than half the prior-year level as receivables swelled. The company also spent $4.9 million repurchasing stock, a choice that looks aggressive alongside new borrowing and a thin $7.0 million cash balance.

The call sharpened both halves of the story:

• **Demand:** Management said for the first time that products are on allocation with existing customers. Q3 grew roughly 19% despite a planned one-week Waukesha shutdown.
• **Growth is decelerating:** Year-over-year growth has stepped down from 36.7% in Q1 to roughly 24% in Q2 and about 19% in Q3. Capacity limits and the lapping of 2025 distribution gains explain much of it.
• **Q4 margin guide:** Q4 gross margin was guided between 18% and 19.5%, with milk costs expected to rise again. Investors should not expect sequential relief before year-end.
• **The EBITDA target went unmentioned:** The $45–50 million fiscal 2027 adjusted EBITDA target reiterated earlier this year did not come up on the call. Management did not withdraw it, but the silence is conspicuous given the margin path.

The recovery case rests almost entirely on 2027, and it has three legs. First, Waukesha bottling speed is slated to more than double from 200 bottles per minute, with upgrades in January and most in February. Management said 2027 should not be a capacity conversation. Second, Lifeway's first broad price increases since 2022 roll in from December through Q1, though some retailers have been hesitant to accept them. Third, management explicitly targets a return to gross margins of 25% or better in 2027, citing pricing, milk stabilization and plant efficiencies. Optionality sits on top of that:

• Talks to expand Costco from a handful of distribution centers to nationwide once capacity allows.
• New shelf space for Farmer Cheese at select Target stores, organic farmer's cheese at Erewhon and Sprouts, Muscle Mates at Kroger and Wegmans, and Kefir Butter at Meijer.

Bears have legitimate ammunition. Execution risk spans construction timing, retailer acceptance of pricing and commodity costs Lifeway does not control.

Market context is thin. No current sentiment reading or post-report price was supplied. Shares opened at $24.04 after the August report, slightly below the 200-day moving average now at $24.56. That suggests the stock entered this report without meaningful momentum in either direction, despite a quarter in which earnings deteriorated sharply.

The bottom line is that Lifeway's demand story is intact and arguably stronger than ever, with customers on allocation and distribution widening. However, the company is producing record revenue at roughly two-thirds of its historic gross margin, funding a plant build with new debt, and guiding to no margin relief in Q4. The investment case has shifted from proven growth to a bet on 2027 execution: pricing that sticks, a Waukesha ramp that arrives on schedule, and milk costs that cooperate. Until gross margin turns, the record sales line is not the number that matters.

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.